Every Form 4 that Vivani Medical, Inc. (VANI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VANI filings page.
Vivani Medical, Inc. (VANI) director Aaron Mendelsohn made a gift transfer of 20,000 common shares to a non-affiliated entity on October 15, 2026. His reported post-transaction position was 168,170 shares directly and 898,317 indirectly; the indirect shares include 150,930 held in five trusts and 747,387 held by MFE, LLC. The footnote says he disclaims pecuniary interest in 20% of MFE, LLC, representing 149,478 shares beneficially owned by other LLC members. No Rule 10b5-1 plan is reported.
Vivani Medical, Inc. granted Chief Business Officer Donald Dwyer equity awards consisting of stock options and performance-based RSUs. He received 70000.0000 common stock options with a 10-year term and a 1.3100 exercise price, vesting 25% after one year and monthly over 36 months, subject to continued service. He also received 35000.0000 RSUs, each a contingent right to one common share, vesting in three stages tied to the share price being at or above $3.15 for three consecutive trading days within four years and additional time-based service conditions.
Vivani Medical, Inc. reported equity awards to Chief Medical Officer Lisa Ellen Porter on July 28, 2026. She received stock options for 80,000 shares at a $1.31 exercise price, vesting 25% after one year and monthly over 36 months within a 10-year term, plus 40,000 performance-based RSUs that vest in three stages if the share price reaches $3.15 for three consecutive trading days within four years.
Vivani Medical, Inc. reported that its Chief Financial Officer Anthony Baldor received equity awards consisting of stock options for 75,000 shares at an exercise price of $1.31 per share and 37,500 performance-based RSUs. The options vest 25% after one year then monthly over 36 months and expire in 2036, while the RSUs vest in three stages only if the stock trades at or above $3.15 for three consecutive trading days within four years.
Vivani Medical, Inc. reported equity compensation for Chief Operations Officer Le Truc consisting of a stock option for 160,000 shares of common stock at an exercise price of $1.31 per share, expiring in 2036, and 80,000 performance-based RSUs tied to achieving a $3.15 share-price hurdle over a four-year term. The option has a 10-year term and vests 25% after one year, then monthly over 36 months, while the RSUs vest in three tranches based on this market condition and time-based anniversaries, subject to continued service.
Vivani Medical, Inc. granted Chief Executive Officer Adam Mendelsohn 200,000 stock options and 100,000 performance-based RSUs on July 28, 2026. The options have a $1.31 exercise price, a 10-year term, and vest 25% after one year then monthly for 36 months. Each RSU equals one share and vests in three stages tied to Vivani's stock trading at or above $3.15 for three consecutive trading days, with additional tranches one and two years after that date; the RSUs expire if this price condition is not met within four years and all vesting requires continued service.
BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.
Vivani Medical, Inc. reported that director Daniel Bradbury received a grant of 7,965 non-qualified stock options to buy common stock at 1.3000 per share. The options have a 10-year term, expire on July 26, 2026, and vest quarterly through December 31, 2026, subject to his continued service. The award, held directly, was issued under the non-employee director compensation policy in lieu of $8,000 in cash retainer fees for increased committee service, leaving him with 7,965 options reported in this grant.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported buying 793,650 shares of common stock in a private sale at $1.26 per share, as disclosed in an August 11, 2025 Share Purchase Agreement. The gross proceeds for this private sale transaction were $999,999.00. Following the purchase, he beneficially owns 41,711,936 shares directly and through several trusts and LLCs, and has voting and dispositive power over all of these shares.
Vivani Medical director August J. Moretti received a grant of non-qualified stock options covering 36,000 shares of common stock at an exercise price of $1.22 per share. The award was made under Vivani’s Non-Employee Director Compensation Policy and vests in monthly installments over three years, with the options expiring on June 23, 2036. This is a compensation-related equity grant rather than an open-market purchase or sale.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported receiving a grant of non-qualified stock options for 36,516 shares of common stock at an exercise price of $1.22 per share. This compensation award was made under the company’s Non-Employee Director Compensation Policy.
The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to Mr. Williams’ continued service through that date, and are scheduled to expire on June 23, 2036.
Vivani Medical, Inc. director Alexandra L. Popoff received an annual non-qualified stock option grant covering 36,516 shares of common stock at an exercise price of $1.22 per share. The option expires on June 23, 2036 and vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to continued service. Following this grant, she holds 36,516 options directly under this award.
Vivani Medical, Inc. director Daniel Bradbury received an annual grant of non-qualified stock options as part of the company’s Non-Employee Director Compensation Policy. The award covers 36,516 options to buy common stock at an exercise price of $1.22 per share, representing 36,516 underlying shares.
The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, Bradbury holds 36,516 options, and the options are scheduled to expire on June 23, 2036.
Vivani Medical, Inc. director Aaron Mendelsohn received a grant of stock options as part of his non-employee director compensation. He was awarded a non-qualified option covering 36,516 shares of common stock at an exercise price of $1.22 per share, held directly.
The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent on continued board service through that date, and expires on June 23, 2036. This is a compensation-related award, not an open-market stock purchase or sale.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported a significant insider purchase of the company’s common stock. He acquired 1,587,301 shares in a private sale at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, for gross transaction value of $1,999,999.26. Following this transaction, he beneficially owns 40,918,286 shares of Vivani common stock directly and through several trusts and LLCs over which he has voting and dispositive power.
Vivani Medical, Inc. director and significant shareholder Gregg Williams bought 1,587,301 shares of common stock at $1.26 per share in a private sale transaction. The footnotes state the gross amount for this transaction was $1,999,999.26.
After these transactions, Williams is reported as owning a total of 39,330,985 Vivani shares directly and indirectly. This includes 4,799,200 shares held personally and additional holdings through several trusts and LLCs over which he has voting and dispositive power.
Vivani Medical, Inc. director and 10% owner Gregg Williams bought 1,587,301 shares of common stock in a private sale at $1.26 per share, under a Share Purchase Agreement dated August 11, 2025. The gross proceeds for this transaction were $1,999,999.26. After the purchase, he beneficially owns a total of 37,743,684 shares, including 4,799,200 shares held directly and additional shares held through several trusts and LLCs over which he has voting and dispositive power.
Vivani Medical director and 10% owner Gregg Williams reported significant open-market purchases of Vivani Medical, Inc. common stock. On two private sale transactions dated in Share Purchase Agreements on May 12, 2025 and August 11, 2025, he purchased 1,310,680 shares at $1.03 per share and 264,551 shares at $1.26 per share, respectively. The related footnotes state gross proceeds of $1,350,000.40 for the first transaction and $333,334.26 for the second. After these transactions, he directly and indirectly controls 36,156,383 shares, including 4,799,200 shares held directly and additional shares held through the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.
Williams Gregg reported open-market purchase transactions in a Form 4 filing for VANI. The filing lists transactions totaling 1,866,492 shares at a weighted average price of $1.06 per share. Following the reported transactions, holdings were 29,781,952 shares.
Vivani Medical director and 10% owner Gregg Williams reported buying 1,351,351 shares of Vivani common stock in a private sale on January 27, 2026. The purchase price was $1.48 per share, matching the last reported Nasdaq sale price on January 23, 2026, for gross proceeds of $1,999,999.48.
After this transaction, Williams beneficially owns 32,714,660 shares directly and through related entities. These include 4,799,200 shares in his own name, 25,789,708 shares held by the Gregg G. Williams 2006 Trust, and additional holdings through several Williams family investment entities over which he has voting and dispositive power.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported additional insider purchases of the company’s common stock. On January 15, 2026, he reported the purchase of 1,473,214 shares at $1.12 per share under a private sale tied to a March 26, 2025 share purchase agreement, with gross proceeds of $1,649,999.68. He also reported purchasing 264,551 shares at $1.26 per share through a separate private sale under an August 11, 2025 share purchase agreement, with gross proceeds of $333,334.26.
After these transactions, Williams is reported as beneficially owning a total of 31,363,309 shares of Vivani Medical common stock. This includes 4,799,200 shares held directly and additional shares held through the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.
Vivani Medical, Inc. disclosed that a director and 10% owner purchased common stock in two private sale transactions. One transaction covered 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated as of March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction covered 264,551 shares at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, with gross proceeds of $333,334.26, in each case priced at the last reported Nasdaq sale price on the day before the agreement date.
Following these purchases, the reporting person beneficially owns 29,625,544 shares of Vivani common stock held directly and through several trusts and investment entities, and Gregg Williams has voting and dispositive power over all of these shares.
Vivani Medical, Inc. insider activity: A reporting person who is both a director and 10% owner of VANI disclosed two private purchases of Vivani Medical common stock dated 11/15/2025. One transaction involved buying 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction involved buying 264,550 shares at $1.26 per share under a Share Purchase Agreement dated August 11, 2025, with gross proceeds of $333,333.00. After these transactions, the reporting person is shown as beneficially owning 27,887,779 shares of Vivani common stock through a combination of direct holdings, family trusts, and related entities over which Gregg Williams has voting and dispositive power.
Vivani Medical (VANI) director and 10% owner Gregg G. Williams reported purchasing 3,703,703 shares of common stock on 10/27/2025 at $1.62 per share in a private sale transaction under a Share Purchase Agreement dated 10/26/2025. The transaction totaled $5,999,998.86.
Following the trade, Williams beneficially owned 26,150,015 shares, comprising 4,799,200 held directly and 21,350,815 held indirectly.